|Articles|March 16, 2015

Western Institutional Review Board Receives ISO 9001:2008 Certification

PRINCETON, N.J., Mar. 16, 2015 – WIRB-Copernicus Group (WCG), the world’s largest provider of regulatory and ethical review services and software to support clinical research, announced today that its Western Institutional Review Board® (WIRB®) company has been certified to ISO 9001:2008 by BSI, confirming that it operates an excellent quality management system.

 

“WIRB and its sister IRB, Copernicus Group, are the only two IRBs to have met ISO quality management standards and to have received ISO 9001:2008 certification,” commented WCG Chairman and CEO Donald A. Deieso, Ph.D. “We are proud to have set a new high bar for quality management in ethical review.”

 

“At WCG, we are always looking for ways to increase efficiencies within the clinical research process while – most importantly – maintaining the highest standards of human subject protection,” added WCG Chief Compliance Officer David Forster, JD, MA, CIP. “Achieving ISO certification is a powerful indicator of our commitment to continuous improvement in all aspects of our operations.”

 

Todd VanderVen, president of BSI Americas, stated, “WIRB is to be congratulated for its achievement of certification to ISO 9001:2008. Given Copernicus Group IRB’s earlier certification, WIRB’s achievement sends a clear message of WCG’s commitment to quality and dedication to continual improvement.”

 

All ISO 9000 standards are based on a series of quality management principles. They require company leaders to establish clear goals and objectives for their quality management system and endeavor to get all their employees involved. Participating companies adopt a strong customer focus with employees aiming not just to meet customer expectations but to exceed them. They also take both a process- and systems-based management approach, and strive for continual improvement in their company’s overall performance, using internal audits to track progress.

 

ISO 9001:2008 is implemented by more than one million companies and organizations in more than 170 countries, according to ISO.


Related to this article

The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.